| |
Carboplatin taxotere herceptin |
|
15. 1. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 1994; 330: 473-7. Bezwoda WR. Randomized controlled trial of high-dose chemotherapy HD-CNVp ; versus standard-dose CAF ; chemotherapy for high risk, surgically treated, primary breast cancer. Proc ASCO 1999; 18: 2a. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents CBP ; with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy AFM ; . Proc Soc Clin Oncol 1996; 15: 121. The Scandinavian Breast Cancer Study Group 9401 Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Soc Clin Oncol 1999; 2. 5. Bell AJ, Oscier D, Figes A, Hambeint T. Use of circulating stem cells to accelerate myeloid recovery after autologous bone marrow transplantation. Br J Haematol 1987; 67: 252-3. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral blood progentior cells mobilised by filgastrim G-CSF on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4. Knechtli CJC, Lumley MA, Baker PJ, Milligan DW. PBSC transplantation versus bone marrow autografting: A cost benefit analysis. Br J Haematolol 1994; 86 Suppl 1 ; : 79. 8. Russell NH, Pacey S. Economic evaluation of peripheral blood stem-cell transplantation for lymphoma. Lancet 1992; 340: 1290. Drummond MF, O' Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, Second Edition. Oxford: Oxford University Press 1997. 10. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10.102. Mayordomo JI, Yubero A, Cajal R et al. Phase I trial of high-dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem-cell rescue. Proc Soc Clin Oncol 1997; 16: 102a Abstr 358 ; . Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9 ; 10: 1871-9. Fields KK, Elfenbein GJ. Lazarus HM et al. Maximum tolerated doses of ifosfamide, carboplatin, and etoposide give over six days folloved by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 1995; 13: 323-32. Brice P, Godin S, Libert O et al. Influence du facteur de croissance granulocytaire sur le cout des autogreffes de moelle en oncohematologie. Presse Med 1994; 23: 1512-5. Uyl-de-Groot CA, Hagenbeek A, Verdonck LF, Rutten FFH Cost-effectiveness of autologous bone marrow transplantation versus CHOP chemotherapy in patients with intermediate and high malignant no-Hodgkin's lymphoma NHL ; . Bruselas: First Meeting of the European Haematology Association, 2 June 1994: 921. Julia A, Bueno J, Gadea N et al. Estudio economico del coste del autotransplante de precursores hematopoyeticos de sangre periferica comparado con el de medula osea. Med Clin Bare ; 1995; 105: 131-5. Meisenberg BR, Ferran K, Hollenbach K et al. Reduced charges and costs associated with outpatient autologous stem-cell transplantattion. Bone Marrow Transplant 1998; 21: 927-32. Gulati SC. Bennet CL. Granulocyte-macrophage colony stimulating factor GM-CSF ; as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116" 177-82. Callaert S, Ravaud P, Viens-Bitker F et al. Cout d'un traitement intensif suivi d'une autogreffe de cellules souches circulantes. Application au myelome multiple. Press Med 1994; 23 15 ; : 694-8. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, second edition. Ottawa: Canadian Coordinating Office for Health Technology Assessment CCOH-TA ; 1997. Harmet European Commission Project ; The Harmonisation by Consensus of the Methodology for Economic Evaluation of Health Care Technologies in the European Union 1998.
Carboplatin treatment
We thank Drs. Margaret L. Kripke and Konrad Muller for critical reading of the manuscript. This work was supported by National Cancer Institute NCI ; Grants SEU-CA112660, SEU-CA75575, and DJMCA69676. The animal facilities at the University of Texas M. D. Anderson Cancer Center are supported in part by NCI Core Grant CA16672
The International Collaborative Ovarian Neoplasm ICON ; trial 175 and the Adjuvant ChemoTherapy In Ovarian Neoplasm Trial.76 Analysis of the combined result showed survival rates of 82% vs 74%, an 8% increase in favor of chemotherapy. The survival rate of patients with stage I disease who experienced disease relapse after observation only was similar to that of patients with stage III disease with salvage of only 20%.140 Current recommendations are for no postoperative treatment of patients with early-stage stage IA and IB ; ovarian cancer with well- or moderately well-differentiated tumors. Postoperative treatment with either paclitaxel plus carboplatin or participation in clinical trials is recommended for patients with early-stage disease with poor prognostic features. Advanced-Stage Disease. Evolution of Chemotherapy for Advanced-Stage Ovarian Cancer. From the 1960s to the present, chemotherapy for ovarian cancer has evolved from single-agent alkylating agent therapy to combination chemotherapy, intraperitoneal therapy, biologic agents, and immunotherapy for patients with advanced disease. Despite these advances, most patients with stage III and IV ovarian cancer are not cured of their disease. Melphalan, chlorambucil, or cyclophosphamide as single agents in advanced ovarian cancer produced response rates of 35% to 65%, with median survival times of 10 to months.141 In the 1970s, combination chemotherapy resulted in improved response rates and survival times compared with single-agent therapy. The first study to show improved survival with combination chemotherapy was published in 1978. The combination of altretamine hexamethylmelamine ; , cyclophosphamide, methotrexate, and fluorouracil was compared with melphalan, with overall response rates of 75% vs 54% and a longer median survival 29 vs 17 months; P .02 ; for the combination.142 Additional combination chemotherapy trials, such as melphalan vs cyclophosphamide, altretamine hexamethylmelamine ; , and fluorouracil143; cyclophosphamide vs cyclophosphamide and doxorubicin144; cyclophosphamide, altretamine hexamethylmelamine ; , doxorubicin Adriamycin ; , and cisplatin vs melphalan145; and melphalan plus doxorubicin Adriamycin ; vs melphalan146; showed improved response rates and in some studies improved median survival with combination therapy.147 In 1982, a study by Decker et al148 at Mayo Clinic reported 2-year survival rates of 52% and 19% with cyclophosphamide plus cisplatinum vs cyclophosphamide alone. In 1986, GOG reported a study of doxorubicin plus cyclophosphamide vs cyclophosphamide, doxorubicin Adriamycin ; , and cisplatin with median survival times of 7.7 vs 13.1 months and an overall survival time of 9.7 vs 15.7 months.149 These studies and a Netherlands Cancer Institute study es760 Mayo Clin Proc.
Carboplatin for injection
Figure 5.2. Specificity of the HPLC-UV assay method for carboplatin in the presence of CO-administered drugs 50 pglmL of each ; . Chromatograms are of plasma ultrafiltrate samples containing carboplatin 8 pglmL ; , and similar samples with ifosfamide and etoposide, and with dexamethasone, dimenhydrinate, nystatin, ondansetron, sulfisoxazole, and trimethoprim.
| Abraxane herceptin carboplatinThe following case report deals with the sudden unexpected unveiling of Wolff Parkinson White EKG pattern in an asymptomatic 15 year old, 50kg, ASA Grade I male patient who was undergoing modified radical mastoidectomy under conventional general anaesthesia. The WPW pattern with a short PR interval and delta waves appeared suddenly after about ten minutes of the start of surgery; it was not accompanied with any cardiovascular compromise and terminated spontaneously after extubation, whereupon, a 12 lead EKG done in the recovery room demonstrated a normal sinus rhythm. The report aims to ascertain the clinical significance and management in case such an arrhythmia is observed for the first time during anaesthesia and reviews literature reporting similar cases. The possible causes which could lead to the unmasking of anomalous atrio-ventricular A-V ; conduction pathways under general or regional anesthesia. are also discussed.
Int.Cl.7 E01C19 10. METHOD AND DEVICE FOR COLD MIXING OF ROAD SURFACING MATERIAL. LEIF PERSSON PLANT I LOMMA AB and carmustine.
See Glossary ; . One Dr Reuven Sandyk * - used a pulsed AC current with good success on a woman in a wheelchair who after two years was able to walk. For the first 30 minute treatment, I set the machine on setting 1 frequency 1. Immediately I noticed a much better colour in my hands and feet. A few weeks later I noticed an increase in energy, more stamina, better concentration and the ability to walk further. Before, I was using a scooter for any distance. I started by using the machine every second day for 30 minutes. Then I went up to using it 5 times a week. The best level to.
| Accounts for its slow in vivo degradation to decarboxylated degradation products. As a result. carboplatin is eliminated primarily via the kidneys into the urine where at least and carteolol.
Nonerror-prone library were sequenced by standard techniques. The plasmids contained intact ORFs with the desired mutations. No additional mutations were detected. With a sample size of 60, we were able to find all of the specified mutations at each designed position. It is impossible to find all combinations of the mutations within this small sample the library contained 172, 800 unique sequences ; , but none of the clones were identical and we were unable to detect a statistically significant bias toward any particular mutation at any position. This result indicates that we have developed an efficient method for converting a PDA-defined library into an experimental library containing all of the mutated genes required to encode the desired mutant sequences. 500, 000 individual E. coli colonies expressing the mu.
Carboplatin weekly dosing
Medicines that relieve nasal congestion, for example, contain the ingredient pseudoephedrine, which can increase a person's heart rate. In particular, individuals with high blood pressure or a history of heart disease must use these products with care. Other medicines contain antihistamines which can cause drowsiness and dizziness. Anyone taking these medications must avoiding drinking alcohol which can and caverject.
Purpose. To define the optimal recombinant human interleukin-3 rhIL-3 ; dose required to intensify the dose of carboplatin and cyclophosphamide chemotherapy for primary advanced epithelial ovarian cancer. Patients and Methods. Seventeen patients were treated on day one with carboplatin dose adjusted for creatinine clearance, range 257-385 mg m2, median 300 mg m2 ; and cyclophosphamide 750 mg m2 ; . RhIL-3 5 g kg day n 10 ; or day n 7 ; was administered subcutaneously on days 2 through 11. Carboplatin dose was to be escalated if no postponement of cycle 1-3 had occurred. Results. A three week chemotherapy interval could be achieved in 62% of the cycles and within a four week interval in 81%, with no difference between the two rhIL-3 doses. A neutrophil nadir less than 0.5 109 l occurred in 35% of the cycles at 5 g day rhIL-3 and in 52% at 10 g kg day N.S. ; . The mean platelet nadir in cycle 1 was 17378 109 l at 5 day rhIL-3 and 340152 109 l at 10 day rhIL-3 p 0.05 ; , with a faster recovery of platelets at 10 g day p 0.05 ; . Progressive myelotoxicity occurred for leukocytes and platelets at both rhIL-3 doses, and required chemotherapy postponement in later cycles. The planned six cycles were completed by 41% of the patients. Fever 38.5C ; occurred in 38% of the cycles at 5 g day rhIL3 and in 97% at 10 g kg day p 0.0005 ; . Headache and myalgias occurred in 30% and 44% of the cycles on 5 and 10 g kg day rhIL-3, respectively. After two cycles, diffuse erythema, facial edema and urticaria was observed in two patients at 5 g day and in five patients at 10 g day rhIL-3. These side effects resolved after discontinuation of rhIL-3 and administration of corticosteroids and antihistamines. Conclusion. A dose of 5 g day rhIL-3 proved to be optimal to intensify the carboplatin and cyclophosphamide regimen. It permitted the administration of carboplatin and cyclophosphamide combination therapy every three weeks in 62% of the cycles.
Amount paid by the primary payer for Medicare covered services amount entered in value codes 12, 13, 14, or 47, as appropriate, Items 46-49 ; . or o Your charges, Item 53 or the amount you are obligated to accept as payment in full when the primary payer pays a lesser amount ; , value code 44, Items 46-49, minus the larger of: -Total Deductions the sum of Items 60-61 or and cefazolin.
And chemotherapy with PCV lomustine procarbazine vincristine ; and temozolomide were treated with 350 mg m2 carboplatin on day 1, and 50 mg m2 teniposide on days 13, every 4 weeks. Results: Response and toxicity were evaluated in all 23 patients enrolled in the study. Two had partial response [8.6%; 95% confidence interval CI ; 1.8% to 28.6%] and 12 stable disease 52.17%; 95% CI 30% to 73% ; . Median time to progression was 19 weeks 95% CI 11.435.0 ; , and 34.8% of the patients 95% CI 20.0% to 61.0% ; had progression-free survival at 6 months. Median survival time was 60.7 weeks 95% CI 39.8 to not achieved ; and 51% of the patients 95% CI 33.5% to 79.7% ; were alive at 12 months. A total of 103 cycles were administered on average 4.4 per patient; range 19 ; . Toxicity was mild and mainly hematological, with grade 4 neutropenia and grade 4 thrombocytopenia in two 8.6% ; and three patients 13% ; , respectively. Conclusions: Although the response rate of combined carboplatin and teniposide chemotherapy in heavily pretreated oligodendroglial tumors is moderate, the toxicity is manageable, and delay of progression in responders or stable patients may still confer a relevant clinical benefit. Key words: carboplatin, chemotherapy, oligodendroglioma, salvage therapy, teniposide.
Carboplatin breast cancer
Advanced colorectal cancer: a Frenchintergroup study. JClin Oncol1997; 15: 808 15. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer. Effects of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537 Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335 Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706 Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238 Herbst RS, Giaccone G, SchillerJH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785 Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer The IDEAL1Trial ; . J Clin Oncol 2003; 21: 2237 Erratum in: JClin Oncol 2004; 22: 4811. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30: 255 Herbst RS, Johnson DH, Mininberg E, et al. Phase I II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1 epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544 and cefprozil.
12. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784793. Heymach JV. ZD6474 clinical experience to date. Br J Cancer 2005; 92 Suppl 1 ; : S14S20. 14. Natale R, Bodkin D, Govindan R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib IressaTM ; in patients with NSCLC: results of a randomized, double blind phase II study. Lung Cancer 2005; 49 Suppl 2 ; : S37 Abstr O-103 ; . 15. Heymach J, West H, Kerr R et al. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized phase II study. Lung Cancer 2005; 49 Suppl 2 ; : S247 Abstr. P-497 ; . 16. Herbst RS, Johnson B, Rowbottom J et al. ZD6474 plus docetaxel with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial. Lung Cancer 2005; 49 Suppl 2 ; : S35 Abstr. O-100 ; . 17. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471478. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327337. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; Published ahead of print on November 28, 2005 as 10.1200 JCO.2005.02.2194. ; 20. Wilhelm SM, Carter C, Tang L et al. BAY 439006 exhibits broad spectrum oral antitumor activity and targets the RAF MEK ERK pathway and receptor tyrosine kinases Involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 70997109. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY439006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 54725480. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 439006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965972. Adjei AA, Mandrekar S, Marks RS et al. A Phase I study of BAY 439006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer NSCLC ; . J Clin Oncol 2005; 23: 208S Abstr. 3067.
Carboplatin side effects
Start Date 1983 Number NMCSD-092 Title Computed tomography and peritoneal lavage in determining severity of visceral injury after blunt abdominal trauma Combination chemotherapy for metastatic recurrent cancer of breast. A randomized phase III trial comparing CAFVATH vs. VATH alternating with CMFVP Cytosine arabinoside and cisplatin for advanced stage breast cancer Mitomycin-C and cisplatin vs. Adriamycin and cisplatin for malignant mesothelioma, phase II Regional stage III NSCLC chemotherapy and radiation therapy vs. radiation therapy alone Approval of final case report on emergency use of investigational drugs methylGAG and ifosphamide Emergency drug use of investigational drug AZQ ICO name redacted ; Cold cardioplegia - effects on phrenic nerve conduction, diaphragm motion, and lung volumes Carboplatin CBDCA ; vs. iproplatin CHIP ; in advanced non-small cancer lung carcinoma, phase II Diagnostic utility of bone scans in sarcoidosis and correlation of bone involvment with disease activity Residual tumor following radiotheraphy for locally advanced carcinomas of the uterine cervix. Progonostic significance Protocol for evaluation of radical mastectomy and total mastectomy with and without radiation in the primary treatment of cancer of the female breast, NSABP B-04 Should single phase radionuclide bone imaging be used in suspected osteomyelitis? Anxiety and cancer treatment: Response to stressful radiotherapy Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: A preliminary report 1985 and ceftriaxone.
5. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169: 9-17. Lane HC, Zunich KM, Wilson W, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus HIV ; infection. Ann Intern Med 1990; 113: 512-9. Lang JM, Touraine JL, Trepo C, et al. Randomised, double-blind, placebocontrolled trial of ditiocarb sodium `Imuthiol' ; in human immunodeficiency virus infection. Lancet 1988; 2: 702-6. Pedersen C, Sandstrm E, Petersen CS, et al. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990; 322: 1757-63. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus HIV ; infection: a randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-11. Lane HC, Davey RT Jr, Sherwin SA, et al. A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome AIDS ; . J Clin Immunol 1989; 9: 35161. Lane HC, Siegel JP, Rook AH, et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Modif 1984; 3: 5126. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991; 4: 11-23. Mazza P, Bocchia M, Tumietto F, et al. Recombinant interleukin-2 rIL-2 ; in acquired immune deficiency syndrome AIDS ; : preliminary report in patients with lymphoma associated with HIV infection. Eur J Haematol 1992; 49: 1-6. Murray HW, Squires KE, Gassyuk-Botev E, DePamphilis JK. Interleukin-2 treatment, interferon-gamma induction, and AIDS monocyte activation. J Med 1992; 93: 234. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-8. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987; 3: 115-24. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169: 9819. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72: 398-403. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferonalpha in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1218-22. Lane HC, Masur H, Gelmann EP, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. J Med 1985; 78: 417-22. Vasudevachari MB, Salzman NP, Woll DR, et al. Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. J Clin Immunol 1993; 13: 185-92. Davey RT Jr, Dewar RL, Reed GF, et al. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697, 661. Proc Natl Acad Sci U S A 1993; 90: 5608-12. Pachl CA, Kern DG, Sheridan PJ, et al. Quantitative detection of HIV RNA in plasma using a signal amplification probe assay. In: Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 1114, 1992. Washington, D.C.: American Society of Microbiology, 1992: 318. abstract. 25. Urdea MS, Wilber JC, Yeghiazarian T, et al. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 1993; 7: Suppl 2: S11-S14. 26. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994; 170: 1172-9. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764-72. Lane HC, Falloon J, Walker RE, et al. Zidovudine in patients with human immunodeficiency virus HIV ; infection and Kaposi sarcoma: a phase II randomized, placebo-controlled trial. Ann Intern Med 1989; 111: 41-50. [Erratum, Ann Intern Med 1990; 112: 388.] Farace F, Angevin E, Escudier B, et al. Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. Int J Cancer 1993; 54: 741-7 and carboplatin.
Carboplatin dose
MPI provides the ability to risk stratify patients and has served to define nuclear cardiology, as a tool beyond the establishment of a clinical diagnosis. A basic goal of any test aimed at providing prognostic information is to permit the separation of a low-risk group of patients from those who are at a high risk of sustaining subsequent cardiac events, such as cardiac death or myocardial infarction. It is to the latter group that we direct our resources, avoiding the expense and risk of subsequent tests and procedures, in those subjects deemed to be at low risk for cardiac events. Effective risk stratification has been shown with exercise or pharmacologic medication-induced ; stress testing simply by determining whether or not the perfusion study is normal or abnormal. A normal myocardial perfusion study is associated with a 0.3% to 1.0% annual risk of myocardial infarction or cardiac-related death, in contradistinction to an abnormal study where the risk is five- to 10-fold increased see Figure 1 ; . A number of studies have demonstrated not only the independent value of MPI in the prediction of subsequent cardiac events, but that this information is incremental to data that may already be available. Thus, perfusion imaging adds to the clinical and exercise data that is already known and strengthens the model for prediction of myocardial infarction or cardiac death. This incremental value extends for up to six years with regards to the prediction of subsequent cardiac events. It appears that computerized, quantitative analysis provides similar prognostic data to that obtained from expert interpretation, thereby providing potential value especially in laboratories with less experienced visual interpreters. The use of gated SPECT to determine both LV volumes and ejection fraction also has incremental prognostic value. In addition to the prognostic applications of perfusion imaging in a general population with known or suspected CAD, this technique has shown specific predictive value with regards to events in female patients and in the elderly. Furthermore, diabetics are at a markedly increased risk of heart disease and, recently, MPI has been shown to successfully identify diabetic patients with CAD and may help in planning treatment strategies for such individuals. The application of scintigraphic techniques early after a myocardial infarction permits selection of patients who should be considered for additional cardiac testing, such as cardiac catheterization prior to hospital discharge. Recent trials continue to demonstrate the value of post-MI risk stratification, even when contemporary therapeutics are employed. Patients with vascular disease have been extensively studied with vasodilator scintigraphy, as this group has a high and celestone
Carboplatin taxol breast cancer
Histidine kinase and ampk, quintox gas analyzer, lymphocytosis pediatric, lithotripsy of america and zonisamide mechanism. Radiate worship backgrounds, bella materna new orleans, congenital adrenal hyperplasia hydroxylase deficiency and pleural effusion news or left handed knitting.
Gemzar carboplatin
Carbpolatin, carboplaitn, carbopla6in, darboplatin, carboplat9n, carb0platin, carboplain, carb9platin, carrboplatin, carboplaatin, carboplahin, carboplat8n, carbopla5in, carbo0latin, cabroplatin, carboplayin, cadboplatin, carbpplatin, acrboplatin, carboplatjn.
Generic Carboplatin
Carboplatin and taxol for lung cancer, carboplatin treatment, carboplatin for injection, abraxane herceptin carboplatin and carboplatin weekly dosing. Carboplatin breast cancer, carboplatin side effects, carboplatin dose and carboplatin taxol breast cancer or gemzar carboplatin.
|
